Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microcrystalline tyrosine as a novel depot-forming agent in venom immunotherapy: a pre-clinical evaluation in bee-venom allergic mice.

Frontiers in allergy·2026
Same author

Carprofen and buprenorphine delivery using micropipette-guided drug administration (MDA) in mice.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Global Healthcare Study on Psoriasis (GHSP): cohort profile and first findings.

BMJ open·2026
Same author

Moving beyond oral gavage: micropipette-guided drug administration (MDA) as a 3R refinement for voluntary oral drug delivery in rodents.

Lab animal·2026
Same author

Patient-Derived IgG Epitope Mapping of Bet v 1 Reveals Hypoallergenic Peptide Candidates for Safe and Next-Generation Allergen Immunotherapy.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

New Generation of Allergen Immunotherapy Using Virus-Like Particles: A Comprehensive Review.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same journal

Biosimilars in allergology: an outline in pediatric patients.

Current opinion in allergy and clinical immunology·2026
Same journal

The immunogenetic landscape of systemic lupus erythematosus.

Current opinion in allergy and clinical immunology·2026
Same journal

Circadian control of innate immunity: molecular mechanisms and implications for allergic disorders.

Current opinion in allergy and clinical immunology·2026
Same journal

Probiotics in allergic disease: from adjunct supplement to immune-modifying strategy (2026 update).

Current opinion in allergy and clinical immunology·2026
Same journal

Updates on drug-induced anaphylaxis in children.

Current opinion in allergy and clinical immunology·2026
Same journal

Beta-lactam de-labelling as a core antimicrobial stewardship strategy in the era of the antimicrobial resistance pandemic: a narrative review.

Current opinion in allergy and clinical immunology·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Intralymphatic immunotherapy.

Gabriela Senti1, Pål Johansen, Thomas M Kündig

  • 1Clinical Trials Center, Center for Clinical Research, University and University Hospital of Zurich, Switzerland. gabriela.senti@usz.ch

Current Opinion in Allergy and Clinical Immunology
|August 15, 2009
PubMed
Summary
This summary is machine-generated.

Intralymphatic immunotherapy (ILIT) offers a safer and faster alternative to traditional allergy treatments. By administering allergens directly into lymph nodes, ILIT reduces treatment duration and allergen dosage, improving patient compliance.

More Related Videos

Intra-lymph Node Injection of Biodegradable Polymer Particles
09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

Related Experiment Videos

Last Updated: Jun 21, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Intra-lymph Node Injection of Biodegradable Polymer Particles
09:06

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

Area of Science:

  • Immunology
  • Allergology
  • Vaccinology

Background:

  • Subcutaneous allergen-specific immunotherapy (SCIT) is effective for IgE-mediated allergies but limited by long treatment durations and risk of systemic reactions.
  • Sublingual immunotherapy offers an alternative but does not reduce treatment duration or frequency.
  • Intralymphatic immunotherapy (ILIT) has emerged as a promising alternative for allergen immunotherapy.

Purpose of the Study:

  • To review the potential of intralymphatic immunotherapy (ILIT) as an alternative to traditional subcutaneous allergen-specific immunotherapy (SCIT).
  • To highlight the advantages of ILIT in enhancing immune responses and improving patient outcomes for allergic conditions.

Main Methods:

  • Review of studies involving direct allergen administration into lymph nodes (ILIT) in animal and human models.
  • Comparison of ILIT efficacy, safety, and patient compliance with SCIT and sublingual immunotherapy.

Main Results:

  • Direct injection into lymph nodes enhances immune responses to various antigens, including allergens.
  • ILIT significantly reduces the required allergen dose and number of administrations compared to SCIT.
  • ILIT is well-tolerated, virtually painless, and easy to perform, leading to improved patient compliance.

Conclusions:

  • Intralymphatic immunotherapy (ILIT) markedly enhances protective immune responses, enabling reduced allergen dosage and injection frequency.
  • ILIT presents a safer, faster, and more convenient immunotherapy option compared to SCIT, significantly improving patient convenience and compliance.